Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis

Journal of Neurology

Volumn 250, Issue 10, 2003, Pages 1190-1194

  Monaca Charley, C ^a   Stojkovic, T ^a   Duhamel, A ^b   De Seze, J ^a   Ferriby, D ^a   Vermersch, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

Cerebellar syndrome; Dolasetron mesilate; Multiple sclerosis

Indexed keywords

DOLASETRON MESILATE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

ADULT; ARTICLE; ATAXIA; BODY MOVEMENT; CEREBELLUM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FUNCTION TEST; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; CEREBELLAR DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUINOLIZINES; REPRODUCIBILITY OF RESULTS; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 0142042849     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0176-3     Document Type: Article

References (16)

1. 3 receptor in porcine brain. Neurosci Lett 269:91-94
2. Gbadamosi J, Buhmann C, Moench A, Heesen C (2001) Failure of ondansetron in treating cerebellar tremor in MS patients - an open-label pilot study. Acta Neurol Scand 104: 308-311
3. Goodkin DE, Hertsgaard D, Seminary J (1988) Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 69:850-854
4. Hökfelt T, Fuxe K (1969) Cerebellar monoamine nerve terminals, a new type of afferent fibers to the cortex cerebelli. Exp Brain Res 9:63-72
5. Kuriyama K, Haber B, Sisken B, Roberts E (1966) The gamma-aminobutyric acid system in rabbit cerebellum. Proc Natl Acad Sci 55: 846-852
6. st ed, Chapman & Hall, London
7. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911
8. Poser CM, Paty DW, Scheinberg L, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
9. Rice GP, Ebers GC (1995) Ondansetron for intractable vertigo complicating acute brainstem disorders. Lancet 345: 1182-1183
10. 3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 62:282-284
11. Trapp BD, Peterson J, Richard BS, Ransohoff M, Rudick R, Mörk S, Bö L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
12. Trouillas P, Garde A, Robert JM, Renaud B, Adeleine P, Bard J, Brudon F (1980) Régression du syndrome cérébelleux sous traitement àlong terme par le 5-HTP ou l'association 5-HTP-Bensérazide: vingt-cinq observations quantifiées et traitées par ordinateur. Rev Neurol (Paris)136:891
13. Trouillas P, Brudon F, Adeleine P (1988) Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol 45:1217-1222
14. Trouillas P, Serratrice G, Laplane D, Rascol A, Augustin P, Barroche G, Clanet M, Degos CF, Desnuelle C, Dumas R, et al. (1995) Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol 52:456-460
15. 1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotoninergic theory of ataxia. Prog Brain Res 114: 589-599
16. 3H]ICS 205-930. Neurosci 31:393-400